A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Infliximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Biomabs Pharmaceuticals
- 18 Sep 2019 Planned End Date changed from 1 Jul 2019 to 30 Oct 2019.
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 16 May 2018 Status changed from not yet recruiting to recruiting.